Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29522085.
- Also identified by DOI 10.1093/cid/cix1051.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.
Medical subject headings
- Antiviral Agents
- Benzimidazoles
- Benzoxazines
- Cytochrome P-450 CYP2B6
- Fluorenes
- Hepatitis C
- Sofosbuvir